水素富化透析液を用いた新規血液透析が慢性透析患者の予後に与える影響：前向き観察研究
A novel haemodialysis system (E-HD) delivering dialysis solution enriched with molecular hydrogen at 30–80 ppb via water electrolysis was evaluated in a non-randomized prospective observational study involving 309 chronic dialysis patients (E-HD: n=161; conventional HD: n=148). Over a mean follow-up of 3.28 years, the composite primary endpoint of all-cause mortality and non-lethal cardio-cerebrovascular events occurred in 41 E-HD patients versus 50 conventional HD patients. Multivariate Cox proportional hazards analysis identified E-HD as an independent predictor of improved prognosis, with a hazard ratio of 0.59 (95% CI: 0.38–0.92) after adjustment for age, cardiovascular history, serum albumin, and C-reactive protein. Post-dialysis hypertension was also reduced in the E-HD group, accompanied by a significant decrease in antihypertensive medication use. These findings suggest that hydrogen-dissolved dialysis solution may favorably influence long-term outcomes in chronic dialysis patients.
Molecular hydrogen is proposed to exert anti-inflammatory effects, which may underlie the observed reductions in post-dialysis hypertension and cardio-cerebrovascular event risk in chronic haemodialysis patients.
Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).
See also:
https://h2-papers.org/en/papers/29321509